Osmetech Plc's Exclusive Warfarin CYP4F2 Biomarker Included in Leading Warfarindosing.org Algorithm

PASADENA, Calif.--(BUSINESS WIRE)--Osmetech plc (LSE:OMH), the international molecular diagnostics company, announces that its exclusive CYP450 4F2 biomarker has been included on the leading warfarin dosing website, www.warfarindosing.org, a free Web site to aid doctors and other clinicians in warfarin therapy by estimating the therapeutic dose in patients new to warfarin or within first 4 INRs.

Back to news